SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-005734 to Celularity Inc (CELU, CELUW) (CIK 0001752828) (CELU)

Celularity Inc (CELU, CELUW) (CIK 0001752828)
Date: May 31, 2023 · CIK: 0001752828 · Accession: 0000000000-23-005734

AI Filing Summary & Sentiment

File numbers found in text: 333-272198

Date
May 31, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Celularity Inc (CELU, CELUW) (CIK 0001752828)

Letter

United States securities and exchange commission logo May 31, 2023 Kyle Fletcher General Counsel Celularity Inc 170 Park Ave Florham Park, New Jersey 07932 Re:Celularity Inc Registration Statement on Form S-3 Filed May 25, 2023 File No. 333-272198 Dear Kyle Fletcher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marianne Sarrazin

Show Raw Text
United States securities and exchange commission logo
May 31, 2023
Kyle Fletcher
General Counsel
Celularity Inc
170 Park Ave
Florham Park, New Jersey 07932
Re:Celularity Inc
Registration Statement on Form S-3
Filed May 25, 2023
File No. 333-272198
Dear Kyle Fletcher:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Marianne Sarrazin